Evidence map›Paper›PMID 38961548›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2024

Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol.

A Savinkina, W Muyindike, J A Hahn, N I Emenyonu, R Fatch, C Ngabirano, J Adong, K R Jacobson, B P Linas

Abstract read
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A SavinkinaPublic Health Modeling Unit, and the, Epidemiology of Microbial Diseases Department, Yale School of Public Health, New Haven, CT, USA.
W MuyindikeMbarara Regional Referral Hospital, Mbarara, Mbarara University of Science and Technology, Mbarara, Uganda.
J A HahnDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, and the, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA.
N I EmenyonuDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, and the.
R FatchDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, and the.
C NgabiranoMbarara University of Science and Technology, Mbarara, Uganda.
J AdongMbarara University of Science and Technology, Mbarara, Uganda.
K R JacobsonBoston University School of Public Health, Boston, MA, Boston University School of Medicine, Boston, MA, Boston Medical Center, Boston, MA, USA.
B P LinasBoston University School of Public Health, Boston, MA, Boston University School of Medicine, Boston, MA, Boston Medical Center, Boston, MA, USA.

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ZACHARY Franklin MEISEL · 2015 to 2026
$20.7M
URBAN ARCH (3/5) Uganda Cohort TB preventive therapy for HIV-infected alcohol users in Uganda: an evaluation of safety tolerability and adherenceU01AA020776 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2011 to 2021
$4.7M
The impact of alcohol consumption on TB treatment outcomesR01AI119037 · NIAID · BOSTON MEDICAL CENTER · PI JACOBSON, KAREN R · 2016 to 2020
$3.3M
Training in Research Program on Alcohol Use by Persons with our at Risk for HIVK24AA022586 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2013 to 2023
$1.8M
NIAAA NIH HHS K24 AA022586NIAAA NIH HHS U01 AA020776NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI119037NIDA NIH HHS P30 DA040500
6 · The paper itself

Abstract

<sec><title>BACKGROUND</title>WHO guidance to defer isoniazid preventive therapy (IPT) among those with regular alcohol use because of hepatotoxicity concerns may exclude many people living with HIV (PLWH) at high TB risk in these settings.</sec><sec><title>OBJECTIVE</title>To evaluate hepatotoxicity during TB preventive therapy (TPT) in PLWH who report alcohol use in Uganda over 10 years.</sec><sec><title>METHODS</title>We developed a Markov model of latent TB infection, isoniazid preventive therapy (IPT - a type of TPT), and TB disease using data from the Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) study. We modeled several treatment scenarios, including no IPT, IPT with liver enzyme monitoring (AST/ALT) during treatment, and IPT with pre-screening using the tuberculin skin test (TST).</sec><sec><title>RESULTS</title>The no IPT scenario had 230 TB deaths/100,000 population over 10 years, which is more than that seen in any IPT scenario. IPT, even with no monitoring, was preferred over no IPT when population TB disease incidence was >50 in 100,000.</sec><sec><title>CONCLUSIONS</title>For PLWH who report alcohol use in high TB burden settings, IPT should be offered, ideally with regular AST/ALT monitoring. However, even if regular monitoring is not possible, IPT is still preferable to no IPT in almost every modeled scenario.</sec>.

Indexed as

Alcohol DrinkingAntitubercular AgentsHIV InfectionsIsoniazidLatent TuberculosisAdultChemical and Drug Induced Liver InjuryFemaleHumansMaleMarkov ChainsMiddle AgedTuberculin TestTuberculosisUgandaYoung AdultAntitubercular AgentsIsoniazid

Identifiers

PMID38961548
PMCPMC11875055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.